$LJPC 10-bagger consolidating at $11.43

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
$LJPC 10-bagger consolidating at $11.43

logo-ljpc-home.png
Website


40% BUY


Shares Outstanding: 15.22M
Float: 8.02M

% Held by Insiders: 35.09%
% Held by Institutions: 17.20%
Shares Short (as of Nov 14, 2014): 579.02K
Short Ratio (as of Nov 14, 2014): 3.20
Short % of Float (as of Nov 14, 2014): 7.00%
Shares Short (prior month): 527.04K


10-Q 11/12/14
Summary

yahoo_finance_en-US_s_f_p_191x21_finance_2x.png

Recent Trades
599675067_stockwatch.jpg

Headlines

Friday, November 21, 2014
LA JOLLA PHARMACEUTICAL CO FinancialsEDGAR Online Financials

Tuesday, November 18, 2014
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, FinancialEDGAR Online

Friday, November 14, 2014
10-Q for La Jolla Pharmaceutical Co.Company Spotlight

Wednesday, November 12, 2014
La Jolla Pharmaceutical posts 3Q lossAP
Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney WeekBusiness Wire
LA JOLLA PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly ReportEDGAR Online
La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate HighlightsBusiness Wire

Monday, November 10, 2014
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2%Zacks

Monday, October 27, 2014
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3%Zacks

Thursday, October 23, 2014
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney WeekBusiness Wire

Wednesday, October 22, 2014
La Jolla (LJPC) Shares March Higher, Can It Continue?Zacks

Tuesday, October 14, 2014
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online
Tuesday, September 16, 2014
La Jolla (LJPC) is Oversold: Can It Recover?Zacks

Monday, September 8, 2014
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment ConferenceBusiness Wire

Sunday, August 31, 2014
Using Mean Reversion and Momentum for Possible AdvantageYahoo Finance Blogs

Friday, August 29, 2014
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to aEDGAR Online
Two Portfolios. Pick One.Yahoo Finance Blogs

Monday, August 25, 2014
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal SyndromeBusiness Wire

Thursday, August 14, 2014
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online
La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial ResultsBusiness Wire
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 44

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Knee Treatment with Overture's Latest System

Updated Category News Views 312

Full Commercial Launch of the OvertureTi Knee Resurfacing System Overture Orthopaedics is making headlines as it proudly announces the full commercial launch of its advanced OvertureTi Knee Resurfacing System. This medical device targets early osteoarthritis and cartilage defects effectively, presenting a breakthrough for patients seeking alternatives to traditional joint...

Continue Reading
Elis SA: Key Insights on Recent Share Buyback Activities

Updated Category News Views 130

Elis SA's Recent Share Buyback Activities Elis SA has made a mark with its recent trading activities associated with its own shares, particularly highlighting a series of transactions carried out during a specified period. Overview of the Buyback Program As part of its strategic financial planning, Elis has engaged in a buyback program that has garnered attention. The...

Continue Reading
Kevin O'Leary's Essential Advice for Startups on Content Investment

Updated Category News Views 262

O'Leary: Tools Are Cheap, But Talent Isn't Entrepreneur and "Shark Tank" star Kevin O'Leary emphasizes a critical insight for startups: while the cost of creating digital content has drastically reduced, the true value comes from the talent that produces it. O'Leary shared his thoughts in a recent video, indicating that although the cost of technology has significantly...

Continue Reading
The St. James Reinvents Lacrosse with Spencer Ford at the Helm

Updated Category News Views 237

The St. James Strengthens Lacrosse Initiatives In an exciting development, The St. James has appointed Spencer Ford as the new Director of Lacrosse, ushering in a transformative approach to lacrosse for both boys and girls. With a vast wealth of experience spanning nearly twenty years, Ford is not only a seasoned professional player but also an accomplished coach and...

Continue Reading
Hudbay Minerals Celebrates Permit Approval for Copper World

Updated Category News Views 119

Hudbay Minerals Receives Final Permit for Copper World Project Hudbay Minerals Inc. (TSX, NYSE: HBM), a prominent player in the mining industry, has taken a significant step forward by securing the final major permit necessary for its Copper World project in Arizona. This milestone not only enhances the company’s operational capacity but also solidifies its commitment...

Continue Reading